When Will AI Replace Biostatisticien ?

AI's impact on biostatisticians is unfolding rapidly. By 2028, we anticipate around 50% of current tasks being automated, marking a significant evolution in the field. This transformation is driven by advanced AI platforms capable of handling complex analyses and study designs.

The early wave of impact, starting as early as 2026, will primarily affect junior biostatisticians. Those with 0-3 years of experience performing routine analyses will see their roles significantly altered as AI takes over standard survival analyses, safety tables, and regulatory submission preparations.

By mid-to-late stages, the profession will shift towards AI-supervised validation and intricate study design. While routine tasks are automated, the demand for expertise in complex study design and AI oversight will grow, requiring biostatisticians to adapt their skill sets.

Junior biostatisticians (0-3 years) performing primarily routine analyses face the most significant impact. Entry-level positions are projected to contract by 25-35% as pharmaceutical companies and CROs leverage AI for faster, more consistent execution of standard statistical tasks.

Conversely, senior biostatisticians (5+ years) with deep therapeutic area expertise (oncology, immunology, rare diseases) and strong regulatory strategy knowledge are well-positioned. Their advanced skills in complex study design and AI oversight ensure their continued relevance and potential for salary increases.

To navigate this evolving landscape, biostatisticians must embrace AI tools and develop new competencies. Focus on AI-supervised validation and become proficient in advanced, complex study design, areas where human expertise remains critical.

Familiarize yourself with platforms like DataRobot Clinical, SAS Viya AI, and specialized clinical trial automation tools. Mastering these technologies will enable you to transition from manual statistical analysis to higher-value tasks, ensuring your career progression.